DiaMedica Therapeutics Inc. (DMAC)
NASDAQ: DMAC · Real-Time Price · USD
7.08
+0.07 (1.00%)
At close: Jul 21, 2026, 4:00 PM EDT
7.08
0.00 (0.00%)
After-hours: Jul 21, 2026, 4:10 PM EDT
DiaMedica Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
35
Market Cap
381.49M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sutro Biopharma | 99.61M |
| Autolus Therapeutics | 92.62M |
| Enanta Pharmaceuticals | 69.21M |
| Prelude Therapeutics | 16.72M |
| Abeona Therapeutics | 14.54M |
| Upstream Bio | 3.32M |
| Compass Therapeutics | 850.00K |
| Inhibikase Therapeutics | 1.00 |
DMAC News
- 4 days ago - DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 4 weeks ago - DiaMedica Therapeutics announces dosing of first two patients in DM199 study - TheFly
- 4 weeks ago - DiaMedica Therapeutics Announces First Patients Dosed in Phase 2 Trial of DM199 for the Treatment of Fetal Growth Restriction - Business Wire
- 5 weeks ago - DiaMedica Therapeutics receives written response from FDA on DM199 - TheFly
- 5 weeks ago - DiaMedica Receives FDA Feedback on DM199 Preeclampsia Nonclinical Program - Business Wire
- 7 weeks ago - DiaMedica Therapeutics Slides: Corporate presentation - Filings
- 7 weeks ago - DiaMedica Therapeutics to Present at the Jefferies Global Healthcare Conference 2026 - Business Wire
- 2 months ago - DiaMedica announces 75% enrollment milestone in ReMEDy2 Phase 2/3 trial - TheFly